drug discovery deep learning

**Deep Learning for Drug Discovery: From Property Prediction to Generative Design — accelerating small-molecule drug development** Deep learning accelerates drug discovery: predicting molecular properties, identifying novel candidates, and optimizing lead compounds. Molecular graph neural networks (GNNs) leverage graph structure; generative models design new molecules with desired properties; physics-informed models predict binding affinity. **Molecular Graph Neural Networks** Molecules represented as graphs: atoms = nodes, bonds = edges. Message Passing Neural Networks (MPNNs) aggregate atom/bond features via neighborhood aggregation: h_i = AGGREGATE([h_j for j in neighbors(i)]). SchNet (continuous filters via Gaussian basis) and DimeNet (directional information) improve over basic MPNN. Graph-level readout (sum/mean pooling) produces molecular representation for property prediction. Regression head predicts continuous properties (solubility, binding affinity); classification head predicts categorical properties (drug-likeness, ADMET). **ADMET Property Prediction** ADMET = Absorption, Distribution, Metabolism, Excretion, Toxicity. High-throughput ML screening accelerates experimental validation. GNNs trained on experimental data (DrugBank, ChEMBL) predict: aqueous solubility (logS), blood-brain barrier penetration (BBB), hepatic clearance, acute toxicity (LD50). Transfer learning leverages pre-trained models (Chemprop). Uncertainty quantification (ensemble predictions) identifies molecules requiring validation. **Generative Molecular Design** Variational Autoencoders (VAE): encoder maps molecule (SMILES string or graph) to latent code; decoder reconstructs molecule. Learned latent space enables interpolation between molecules, traversing property landscape. Flow models: learned invertible function maps SMILES to latent; gradient updates in latent space optimize properties. Diffusion models (DiffSBDD): iteratively add Gaussian noise to molecular graph, learn reverse (denoising) process. Conditional diffusion: guide generation toward target protein pocket (structure-based drug design). **Protein-Ligand Docking Score Prediction** DiffDock (Corso et al., 2023): diffusion model for 3D ligand-pose prediction. Contrary to molecular generation (1D SMILES or 3D graphs), DiffDock places known ligand into protein binding pocket. Input: protein (3D coordinates), ligand (3D structure). Noising: iteratively perturb ligand position/rotation; denoising: predict clean pose. Outperforms classical docking (GNINA, AutoDock Vina) in accuracy and speed. **De Novo Drug Design** Reinforcement learning (RL): generative model as policy, reward = predicted ADMET + binding affinity. Policy gradient training: sample molecules, compute rewards, update policy toward high-reward samples. Scaffold hopping: identify parent compound, generate structural variants maintaining scaffolds while optimizing properties. Foundation models (ChemBERTa—BERT on SMILES, MolBERT) enable transfer learning, reducing fine-tuning data requirements. Clinical trial success: compounds optimized via ML show modest 5-10% improvement over traditional discovery (nature 2023 survey).